论文部分内容阅读
目的观察二甲双胍对2型糖尿病患者血清内脂素水平的影响。方法选取68例新诊断2型糖尿病患者,随机分为对照组和二甲双胍治疗组,每组34例。对照组给予胰岛素治疗,而治疗组在使用胰岛素的基础上加用盐酸二甲双胍1 500 mg/d口服,治疗12周,检测治疗前后空腹内脂素水平的变化。结果治疗12周后,两组的空腹血糖(二甲双胍组:10.34±3.25 mmol/L VS 7.42±2.56 mmol/L,P<0.01;对照组:10.22±2.94 mmol/L VS 8.63±2.15 mmol/L,P<0.05)、餐后2h血糖(二甲双胍组:16.34±2.95 mmol/L VS 9.63±2.69 mmol/L,P<0.01;对照组:16.56±3.02 mmol/L VS 10.96±3.11 mmol/L,P<0.01)均明显下降,但二甲双胍组效果优于对照组,与对照组比较,差异有统计学意义(P<0.01)。另外,二甲双胍组的体质指数(27.12±3.25 kg/m2 VS 22.56±2.88 kg/m2,P<0.01)、胰岛素抵抗指数(6.05±1.68 VS 4.02±1.52,P<0.01)、甘油三酯(2.08±0.89 mmol/L VS 1.59±0.75 mmol/L,P<0.01)和内脂素(188.56±25.68 ng/ml VS 98.26±18.64 ng/ml,P<0.01)水平均较治疗前下降,高密度脂蛋白胆固醇(1.52±0.75 mmol/L VS 1.96±0.81 mmol/L,P<0.01)较治疗前升高;而对照组的BMI、HOMA-IR、血脂和内脂素水平,在治疗前后无明显变化(P>0.05)。结论二甲双胍具有降低内脂素的作用,可能与其改善胰岛素抵抗的作用机制有关。
Objective To observe the effect of metformin on serum visfatin in type 2 diabetic patients. Methods Sixty-eight newly diagnosed type 2 diabetic patients were randomly divided into control group and metformin-treated group, 34 cases in each group. The control group was treated with insulin, while the treatment group was treated with metformin hydrochloride 1 500 mg / d on the basis of insulin for 12 weeks. The changes of fasting visfatin levels before and after treatment were measured. Results After 12 weeks of treatment, the fasting blood glucose (metformin group: 10.34 ± 3.25 mmol / L vs 7.42 ± 2.56 mmol / L, P <0.01) and the control group: 10.22 ± 2.94 mmol / L vs 8.63 ± 2.15 mmol / L (P <0.05), 2h postprandial blood glucose (Metformin group: 16.34 ± 2.95 mmol / L VS 9.63 ± 2.69 mmol / L, P <0.01; control group: 16.56 ± 3.02 mmol / L VS 10.96 ± 3.11 mmol / L, P < 0.01) were significantly decreased, but metformin group better than the control group, compared with the control group, the difference was statistically significant (P <0.01). In addition, the body mass index of metformin group (27.12 ± 3.25 kg / m 2 vs 22.56 ± 2.88 kg / m 2, P <0.01), insulin resistance index (6.05 ± 1.68 vs 4.02 ± 1.52, P <0.01) 0.89 mmol / L vs 1.59 ± 0.75 mmol / L, P0.01) and visfatin (188.56 ± 25.68 ng / ml vs 98.26 ± 18.64 ng / ml, P <0.01) Cholesterol (1.52 ± 0.75 mmol / L VS 1.96 ± 0.81 mmol / L, P <0.01) increased compared with those before treatment, while the levels of BMI, HOMA-IR, lipids and visfatin in the control group did not change significantly P> 0.05). Conclusion Metformin has the effect of reducing visfatin, which may be related to its mechanism of improving insulin resistance.